Herbal preparations for obesity: Are they useful?

Primary Care - Clinics in Office Practice

Volumn 30, Issue 2, 2003, Pages 441-463

  Heber, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEPRAMONE; CAFFEINE; CAFFEINE PLUS EPHEDRINE; CAPSAICIN; CATECHIN; CHITOSAN; CITRUS FRUIT EXTRACT; DEXFENFLURAMINE; ELSINORE PILL; EPHEDRA EXTRACT; EPHEDRINE; GUARANA EXTRACT; HERBACEOUS AGENT; HYDROXYCITRIC ACID; HYPERICUM PERFORATUM EXTRACT; LINOLEIC ACID; METHYLXANTHINE; PHENOBARBITAL; PHENYLEPHRINE; THEOPHYLLINE; UNCLASSIFIED DRUG;

AGITATION; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIETARY FIBER; DRUG EFFICACY; DRUG SAFETY; EPHEDRA SINICA; EUPHORIA; GUARANA; HEADACHE; HEART PALPITATION; HERBAL MEDICINE; HUMAN; HYPERTENSION; INSOMNIA; MUSCLE WEAKNESS; OBESITY; PLANT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEIZURE; SIDE EFFECT; SOUR ORANGE; STROKE; SUDDEN DEATH; TACHYCARDIA; TEA; TREMOR; VERTIGO; WEIGHT REDUCTION; XEROSTOMIA;

EID: 0038053196     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0095-4543(03)00015-0     Document Type: Review

References (118)

1. Vansal SS, Feller DR. Direct effects of ephedrine isomers on human beta-adrenergic receptor subtypes. Biochem Pharmacol 1999;58:807-10.
2. Boozer CN, Nasser JA, Heymsfield SB, et al. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. Int J Obes Relat Metab Disord 2001;25:316-24.
3. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000;343:1833-8.
4. Boozer CN, Daly PA, Homel P, et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int J Obes 2002;26:593-604.
5. Malchow-Moller A, Larsen S, Hey H, et al. Ephedrine as an anorectic: the story of the "Elsinore pill". Int J Obes 1981;5:183-7.
6. Goodman L, Gilman A. The pharmacological basis of therapeutics. 7th edition. New York: Macmillan Publishing Company; 1985.
7. Miller DS. A controlled trial using ephedrine in the treatment of obesity [letter]. Int J Obes 1986;10:159-60.
8. Drug topics red book. Montvale (NJ): Medical Economics Company, Inc.; 2000.
9. Macdonald IA. Advances in our understanding of the role of the sympathetic nervous system in obesity. Int J Obes Relat Metab Disord 1995;19(Suppl 7):S2-7.
10. Chen MD, Lin WH, Song YM, et al. Effect of caffeine on the levels of brain serotonin and catecholamine in the genetically obese mice. Chung Hua I Hsueh Tsa Chih 1994;53:257-61.
11. Oberman Z, Herzberg M, Jaskolka H, et al. Changes in plasma cortisol, glucose and free fatty acids after caffeine ingestion in obese women. Isr J Med Sci 1975;11:33-6.
12. Acheson KJ, Zahorska-Markiewicz B, Pittet P, et al. Caffeine and coffee: their influence on metabolic rate and substrate utilization in normal weight and obese individuals. Am J Clin Nutr 1980;33:989-97.
13. Jung RT, Shetty PS, James WP, et al. Caffeine: its effect on catecholamines and metabolism in lean and obese humans. Clin Sci 1981;60:527-35.
14. Dulloo AG, Geissler CA, Horton T, et al. Normal caffeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers. Am J Clin Nutr 1989;49:44-50.
15. Bracco D, Ferrarra JM, Arnaud MJ, et al. Effects of caffeine on energy metabolism, heart rate, and methylxanthine metabolism in lean and obese women. Am J Physiol 1995; 269:E671-8.
16. Bondi M, Grugni G, Velardo A, et al. Adrenomedullary response to caffeine in prepubertal and pubertal obese subjects. Int J Obes Relat Metab Disord 1999;23:992-6.
17. Tagliabue A, Terracina D, Cena H, et al. Coffee induced thermogenesis and skin temperature. Int J Obes Relat Metab Disord 1994;18:537-41.
18. Yoshida T, Sakane N, Umekawa T, et al. Relationship between basal metabolic rate, thermogenic response to caffeine, and body weight loss following combined low calorie and exercise treatment in obese women. Int J Obes Relat Metab Disord 1994; 18:345-50.
19. Abernethy DR, Todd EL, Schwartz JB. Caffeine disposition in obesity. Br J Clin Pharmacol 1985;20:61-6.
20. Cheymol G. Clinical pharmacokinetics of drugs in obesity. An update. Clin Pharmacokinet 1993;25:103-14.
21. Caraco Y, Zylber-Katz E, Berry EM, et al. Caffeine pharmacokinetics in obesity and following significant weight reduction. Int J Obes Relat Metab Disord 1995;19:234-9.
22. Haffner SM, Knapp JA, Stern MP, et al. Coffee consumption, diet, and lipids. Am J Epidemiol 1985;122:1-12.
23. La Vecchia C, Franceschi S, Decarli A, et al. Risk factors for myocardial infarction in young women. Am J Epidemiol 1987;125:832-43.
24. Noble R. A controlled clinical trial of the cardiovascular and psychological effects of phenylpropanolamine and caffeine. Drug Intell Clin Pharm 1988;22:296-9.
25. Barrett-Connor E, Chang JC, Edelstein SL. Coffee-associated osteoporosis offset by daily milk consumption. The Rancho Bernardo Study. JAMA 1994;271:280-3.
26. Sawynok J. Pharmacological rationale for the clinical use of caffeine. Drugs 1995;49:37-50.
27. Massoudi M, Miller DS. Ephedrine, a thermogenic and potential slimming drug. Proc Nutr Soc 1977;36:135A.
28. Yen TT, McKee MM, Bemis KG. Ephedrine reduces weight of viable yellow obese mice (Avy/a). Life Sci 1981;28:119-28.
29. Wilson S, Arch JR, Thurlby PL. Genetically obese C57BL/6 ob/ob mice respond normally to sympathomimetic compounds. Life Sci 1984;35:1301-9.
30. Massoudi M, Evans E, Miller DS. Thermogenic drugs for the treatment of obesity: screening using obese rats and mice. Ann Nutr Metab 1983;27:26-37.
31. Dulloo AG, Miller DS. Thermogenic drugs for the treatment of obesity: sympathetic stimulants in animal models. Br J Nutr 1984;52:179-96.
32. Liu YL, Toubro S, Astrup A, et al. Contribution of beta 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans. Int J Obes Relat Metab Disord 1995;19:678-85.
33. Bukowiecki L, Jahjah L, Follea N. Ephedrine, a potential slimming drug, directly stimulates thermogenesis in brown adipocytes via beta-adrenoreceptors. Int J Obes 1982;6:343-50.
34. Bailey CJ, Thornburn CC, Flatt PR. Effects of ephedrine and atenolol on the development of obesity and diabetes in ob/ob mice. Gen Pharmacol 1986;17:243-6.
35. Dulloo AG, Miller DS. Aspirin as a promoter of ephedrine-induced thermogenesis: potential use in the treatment of obesity. Am J Clin Nutr 1987;45:564-9.
36. Sapeika N. Drugs in obesity. S Afr Med J 1974;48:2027-30.
37. Astrup A, Lundsgaard C, Madsen J, et al. Enhanced thermogenic responsiveness during chronic ephedrine treatment in man. Am J Clin Nutr 1985;42:83-94.
38. Astrup A, Madsen J, Holst JJ, et al. The effect of chronic ephedrine treatment on substrate utilization, the sympathoadrenal activity, and energy expenditure during glucose-induced thermogenesis in man. Metabolism 1986;35:260-5.
39. Pasquali R, Baraldi G, Cesari MP, et al. A controlled trial using ephedrine in the treatment of obesity. Int J Obes 1985;9:93-8.
40. Pasquali R, Cesari MP, Besteghi L, et al. Thermogenic agents in the treatment of human obesity: preliminary results. Int J Obes 1987;11:23-6.
41. Pasquali R, Cesari MP, Melchionda N, et al. Does ephedrine promote weight loss in low-energy-adapted obese women? Int J Obes 1987;11:163-8.
42. Pasquali R, Casimirri F, Melchionda N, et al. Effects of chronic administration of ephedrine during very-low-calorie diets on energy expenditure, protein metabolism and hormone levels in obese subjects. Clin Sci (Colch) 1992;82:85-92.
43. Nielsen B, Astrup A, Samuelsen P, et al. Effect of physical training on thermogenic responses to cold and ephedrine in obesity. Int J Obes Relat Metab Disord 1993;17:383-90.
44. Astrup A, Breum L, Toubro S, et al. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes Relat Metab Disord 1992;16:269-77.
45. Toubro S, Astrup A, Breum L, et al. The acute and chronic effects of ephedrine/caffeine mixtures on energy expenditure and glucose metabolism in humans. Int J Obes Relat Metab Disord 1993;17(Suppl 3):S73-7; discussion, S82.
46. Astrup A, Toubro S, Christensen NJ, et al. Pharmacology of thermogenic drugs. Am J Clin Nutr 1992;55:246S-8.
47. Astrup A, Toubro S. Thermogenic, metabolic, and cardiovascular responses to ephedrine and caffeine in man. Int J Obes Relat Metab Disord 1993;17(Suppl 1):S41-3.
48. Daly PA, Krieger DR, Dulloo AG, et al. Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity. Int J Obes Relat Metab Disord 1993; 17(Suppl 1):S73-8.
49. Astrup A, Buemann B, Christensen NJ, et al. The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women. Metabolism 1992;41:686-8.
50. Buemann B, Marckmann P, Christensen NJ, et al. The effect of ephedrine plus caffeine on plasma lipids and lipoproteins during a 4.2 MJ/day diet. Int J Obes Relat Metab Disord 1994;18:329-32.
51. Molnar D. Effects of ephedrine and aminophylline on resting energy expenditure in obese adolescents. Int J Obes Relat Metab Disord 1993;17(Suppl 1):S49-2.
52. Molnar D, Torok K, Erhardt E, et al. Safety and efficacy of treatment with an ephedrine/caffeine mixture. The first double-blind placebo-controlled pilot study in adolescents. Int J Obes Relat Metab Disord 2000;24:1573-8.
53. Atkinson RL, Blank RC, Loper JF, et al. Combined drug treatment of obesity. Obes Res 1995;3(Suppl 4):497S-500.
54. Breum L, Pedersen JK, Ahlstrom F, et al. Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice. Int J Obes Relat Metab Disord 1994;18:99-103.
55. Greenway FL, Ryan DH, Bray GA, et al. Pharmaceutical cost savings of treating obesity with weight loss medications. Obes Res 1999;7:523-31.
56. Svendsen TL, Ingerslev J, Mork A. Is Letigen contraindicated in hypertension? A double-blind, placebo controlled multipractice study of Letigen administered to normotensive and adequately treated patients with hypersensitivity. Ugeskr Laeger 1998;160:4073-5.
57. Ryan DH. Medicating the obese patient. Endocrinol Metab Clin North Am 1996;25:989-1004.
58. Davis R, Faulds D. Dexfenfluramine. An updated review of its therapeutic use in the management of obesity. Drugs 1996;52:696-724.
59. Finer N. Present and future pharmacological approaches. Br Med Bull 1997;53:409-32.
60. Carek PJ, Dickerson LM. Current concepts in the pharmacological management of obesity. Drugs 1999;57:883-904.
61. Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev 1999;20:805-75.
62. Bray GA. Drug treatment of obesity. Baillieres Best Pract Res Clin Endocrinol Metab 1999;13:131-48.
63. Astrup A, Lundsgaard C. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice. Exp Clin Endocrinol Diabetes 1998;106:29-34.
64. Astrup AV. Treatment of obesity with thermogenic agents [editorial]. Nutrition 1989; 5:70.
65. Dulloo AG, Miller DS. Ephedrine, caffeine and aspirin: "over-the-counter" drugs that interact to stimulate thermogenesis in the obese. Nutrition 1989;5:7-9.
66. Dulloo AG. Ephedrine, xanthines and prostaglandin-inhibitors: actions and interactions in the stimulation of thermogenesis. Int J Obes Relat Metab Disord 1993;17(Suppl 1): S35-40.
67. Astrup A, Breum L, Toubro S. Pharmacological and clinical studies of ephedrine and other thermogenic agonists. Obes Res 1995;3(Suppl 4):537S-40S.
68. Astrup A, Breum L, Toubro S, et al. Ephedrine and weight loss. Int J Obes Relat Metab Disord 1992;16:715.
69. Toubro S, Astrup A. Randomised comparison of diets for maintaining obese subjects' weight after major weight loss: ad lib, low fat, high carbohydrate diet v fixed energy intake. BMJ 1997;314:29-34.
70. Steele VE, Kelloff GJ, Balentine D, et al. Comparative chemopreventive mechanisms of green tea, black tea and selected polyphenol extracts measured by in vitro bioassays. Carcinogenesis 2000;21:63-7.
71. Sesso HD, Gaziano JM, Buring JE, et al. Coffee and tea intake and the risk of myocardial infarction. Am J Epidemiol 1999;149:162-7.
72. Borchardt RT, Huber JA. Catechol O-methyltransferase. 5. Structure-activity relationships for inhibition by flavonoids. J Med Chem 1975;18:120-2.
73. Dulloo AG, Seydoux J, Giradier L. Tealine and thermogenesis: interactions between polyphenols caffeine and sympathetic activity. Int J Obes Relat Metab Disord 1996;20(Suppl 4):71.
74. Han LK, Takaku T, Li J, et al. Anti-obesity action of oolong tea. Int J Obes Relat Metab Disord 1999;23:98-105.
75. Colker C, Kalman D, Torina G, et al. Effects of Citrus aurantium extract, caffeine and St. John's wort on body fat loss, lipid levels and mood state in overweight healthy adults. Curr Ther Res 1999;60:145-53.
76. Henry CJ, Emery B. Effect of spiced food on metabolic rate. Hum Nutr Clin Nutr 1986;40:165-8.
77. Yoshioka M, St-Pierre S, Suzuki M, et al. Effects of red pepper added to high-fat and high-carbohydrate meals on energy metabolism and substrate utilization in Japanese women. Br J Nutr 1998;80:503-10.
78. Choi Y, Kim YC, Han YB, et al. The trans-10,cis-12 isomer of conjugated linoleic acid downregulates stearoyl-CoA desaturase 1 gene expression in 3T3-L1 adipocytes. J Nutr 2000;130:1920-4.
79. Griinari JM, Corl BA, Lacy SH, et al. Conjugated linoleic acid is synthesized endogenously in lactating dairy cows by Delta(9)-desaturase. J Nutr 2000;130:2285-91.
80. Dhiman TR, Satter LD, Pariza MW, et al. Conjugated linoleic acid (CLA) content of milk from cows offered diets rich in linoleic and linolenic acid. J Dairy Sci 2000;83:1016-27.
81. Kritchevsky D. Antimutagenic and some other effects of conjugated linoleic acid. Br J Nutr 2000;83:459-65.
82. MacDonald HB. Conjugated linoleic acid and disease prevention: a review of current knowledge. J Am Coll Nutr 2000;19:111S-8S.
83. Pariza MW, Park Y, Cook ME. Conjugated linoleic acid and the control of cancer and obesity. Toxicol Sci 1999;52:107-10.
84. Park Y, Storkson JM, Albright KJ, et al. Evidence that the trans-10, cis-12 isomer of conjugated linoleic acid induces body composition changes in mice. Lipids 1999;34:235-41.
85. Park Y, Albright KJ, Liu W, et al. Effect of conjugated linoleic acid on body composition in mice. Lipids 1997;32:853-8.
86. West DB, Delany JP, Camet PM, et al. Effects of conjugated linoleic acid on body fat and energy metabolism in the mouse. Am J Physiol 1998;275:R667-72.
87. DeLany JP, Blohm F, Truett AA, et al. Conjugated linoleic acid rapidly reduces body fat content in mice without affecting energy intake. Am J Physiol 1999;276:R1172-79.
88. Yamasaki M, Mansho K, Mishima H, et al. Dietary effect of conjugated linoleic acid on lipid levels in white adipose tissue of Sprague-Dawley rats. Biosci Biotechnol Biochem 1999;63:1104-6.
89. Tsuboyama-Kasaoka N, Takahashi M, Tanemura K, et al. Conjugated linoleic acid supplementation reduces adipose tissue by apoptosis and develops lipodystrophy in mice. Diabetes 2000;49:1534-42.
90. Satory DL, Smith SB. Conjugated linoleic acid inhibits proliferation but stimulates lipid filling of murine 3T3-L1 preadipocytes. J Nutr 1999;129:92-7.
91. Azain MJ, Hausman DB, Sisk MB, et al. Dietary conjugated linoleic acid reduces rat adipose tissue cell size rather than cell number. J Nutr 2000;130:1548-54.
92. Sullivan C, Triscari J. Metabolic regulation as a control for lipid disorders. I. Influence of (-)-hydroxycitrate on experimentally induced obesity in the rodent. Am J Clin Nutr 1977;30:767-76.
93. Badmaev V, Majeed M. Open field, physician-controlled clinical evaluation of botanical weight loss formula citrin. Nutracon: Nutraceuticals, dietary supplements and functional foods. [Abstract] Las Vegas: Nutracon; 1995.
94. Kriketos AD, Thompson HR, Greene H, et al. Hydroxycitric acid does not affect energy expenditure and substrate oxidation in adult males in a post-absorptive state. Int J Obes Relat Metab Disord 1999;23:867-73.
95. Heymsfield SB, Allison DB, Vasselli JR, et al. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. JAMA 1998;280:1596-600.
96. Van Itallie TB. Dietary fiber and obesity. Am J Clin Nutr 1978;31:S43-2.
97. Ludwig DS, Peterson KE, Gortmaker SL. Relation between consumption of sugar-sweetened drinks and childhood obesity: a prospective, observational analysis. Lancet 2001;357:505-8.
98. Krotkiewski M. Effect of guar gum on body-weight, hunger ratings and metabolism in obese subjects. Br J Nutr 1984;52:97-105.
99. Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on obese patients: a clinical study. Int J Obes 1984;8:289-93.
100. Cairella M, Marchini G. Evaluation of the action of glucomannan on metabolic parameters and on the sensation of satiation in overweight and obese patients. Clin Ter 1995;146:269-74.
101. Hylander B, Rossner S. Effects of dietary fiber intake before meals on weight loss and hunger in a weight-reducing club. Acta Med Scand 1983;213:217-20.
102. Porikos K, Hagamen S. Is fiber satiating? Effects of a high fiber preload on subsequent food intake of normal-weight and obese young men. Appetite 1986;7:153-62.
103. Witkowska A, Borawska MH. The role of dietary fiber and its preparations in the protection and treatment of overweight. Pol Merkuriusz Lek 1999;6:224-6.
104. Pasman WJ, Saris WH, Wauters MA, et al. Effect of one week of fibre supplementation on hunger and satiety ratings and energy intake. Appetite 1997;29:77-87.
105. Baron JA, Schori A, Crow B, et al. A randomized controlled trial of low carbohydrate and low fat/high fiber diets for weight loss. Am J Public Health 1986;76:1293-6.
106. Rigaud D, Ryttig KR, Angel LA, et al. Overweight treated with energy restriction and a dietary fibre supplement: a 6-month randomized, double-blind, placebo-controlled trial. Int J Obes 1990;14:763-9.
107. Solum TT, Ryttig KR, Solum E, et al. The influence of a high-fibre diet on body weight, serum lipids and blood pressure in slightly overweight persons. A randomized, double-blind, placebo-controlled investigation with diet and fibre tablets (DumoVital). Int J Obes 1987;11:67-71.
108. Rossner S, von Zweigbergk D, Ohlin A, et al. Weight reduction with dietary fibre supplements. Results of two double-blind randomized studies. Acta Med Scand 1987; 222:83-8.
109. Gropper SS, Acosta PB. The therapeutic effect of fiber in treating obesity. J Am Coll Nutr 1987;6:533-5.
110. Ryttig KR, Tellnes G, Haegh L, et al. A dietary fibre supplement and weight maintenance after weight reduction: a randomized, double-blind, placebo-controlled long-term trial. Int J Obes 1989;13:165-71.
111. Quaade F, Vrist E, Astrup A. Dietary fiber added to a very-low caloric diet reduces hunger and alleviates constipation. Ugeskr Laeger 1990;152:95-8.
112. Pasman WJ, Westerterp-Plantenga MS, Muls E, et al. The effectiveness of long-term fibre supplementation on weight maintenance in weight-reduced women. Int J Obes Relat Metab Disord 1997;21:548-55.
113. Miller WC, Niederpruem MG, Wallace JP, et al. Dietary fat, sugar, and fiber predict body fat content. J Am Diet Assoc 1994;94:612-5.
114. Alfieri MA, Pomerleau J, Grace DM, et al. Fiber intake of normal weight, moderately obese and severely obese subjects. Obes Res 1995;3:541-7.
115. Han LK, Kimura Y, Okuda H. Reduction in fat storage during chitin-chitosan treatment in mice fed a high-fat diet. Int J Obes Relat Metab Disord 1999;23:174-9.
116. Wuolijoki E, Hirvela T, Ylitalo P. Decrease in serum LDL cholesterol with microcrystalline chitosan. Methods Find Exp Clin Pharmacol 1999;21:357-61.
117. Pittler MH, Abbot NC, Harkness EF, et al. Randomized, double-blind trial of chitosan for body weight reduction. Eur J Clin Nutr 1999;53:379-81.
118. Guerciolini R, Radu-Radulescu L, Boldrin M, et al. Comparative evaluation of fecal fat excretion induced by orlistat and chitosan. Obes Res 2001;9(6):364-7.